The Switzerland-based giant’s CEO defends the purchase of Avidity after one of the deal’s major assets, del-desiran, failed in a study for myotonic dystrophy type 1.
The Switzerland-based giant’s CEO defends the purchase of Avidity after one of the deal’s major assets, del-desiran, failed in a study for myotonic dystrophy type 1.